If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
US FDA approval based on NEURO-TTRansform Phase III results
The plant is yet to start commercial operations
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring
Subscribe To Our Newsletter & Stay Updated
